Innovate UK

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

They care for carers all over the UK with whatever complex needs they may have. They help carers to find carer support resources within their local communities, as well as nationally or with their organisation. All of their solutions deliver to UK addresses, so there is no need for carers and their loved ones to leave the comfort of their own homes to access carer support.

BERRI is a digital toolkit that can identify, track, and support children's psychological needs, as well as provide personalized reports to their carers. It analyses children and young people's needs in areas such as behavior, emotional well-being, relationships, risk, and indicators of underlying disorders.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.

PhysioMedics is a healthcare technology company focused on enhancing the management of musculoskeletal disorders through its online software solutions. The company has developed a self-assessment platform that offers data analytics, personalized self-help advice, and information to connect back pain sufferers with appropriate treatment pathways. This approach enables patients to take an active role in their healthcare, leading to improved outcomes. Additionally, PhysioMedics' platform assists organizations in reducing costs associated with absenteeism and enhances overall efficiency in managing musculoskeletal conditions.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

MiiCare is an innovative company that has developed an AI-powered Home Care Platform tailored for older adults, their families, and caregivers. This platform aims to transform living spaces into safe and connected environments, promoting active aging through a focus on prevention and personalized care. MiiCare integrates various technologies, including telehealth devices, passive sensors, and acoustic sensing, to monitor health determinants such as physical environment, vital signs, and mental well-being. Central to its approach is a conversational AI named Monica, which serves as a Digital Health Coach. Monica engages with users to ensure medication adherence, encourage healthy habits, and provide personalized digital therapeutic content. By enabling remote care delivery and comprehensive assessments of well-being, MiiCare supports caregivers in reducing costs and hospitalizations while enhancing the overall quality of care for aging individuals.

Decorte Future Industries is a venture-backed startup focused on utilizing artificial intelligence to extract health data from sound. The company has developed advanced machine-learning methods that enable the extraction of complex biometrics, including cardiovascular and respiratory health, from audio recorded via standard microphones. This innovative approach allows clients to gather intricate health data efficiently and at scale, simplifying the process of health monitoring.

Gendius Ltd. is a company based in Macclesfield, United Kingdom, founded in 2011 by Chris Genders and Rory Cameron. It specializes in developing app-based solutions for individuals living with diabetes. The company's flagship product, Intellin, is an innovative platform that leverages a user’s clinical history to identify personal high-risk areas for diabetes-related complications. By focusing on these specific risks, Intellin guides users through clinically validated tasks and measures aimed at slowing the progression of their condition, thereby enhancing their quality of life and management of diabetes.

BFB Labs provides state of the art digital therapeutics for better youth mental health, creating a new way of building resilience in a whole generation. Our products fuse evidence-based therapeutic approaches with immersive and responsible gaming making them highly engaging, scientifically robust and cost-effective.

AccuRx is a healthcare communication platform that facilitates seamless interaction between patients and healthcare professionals. The platform enables users to send SMS messages, conduct video consultations, manage appointment bookings, and distribute medical surveys. It also supports the organization of outpatient clinics, virtual wards, and follow-up pathways, enhancing the overall efficiency of primary care. With its adoption by 98% of GP practices and 50% of NHS trusts, AccuRx plays a crucial role in improving communication and collaboration in patient care, ensuring that all parties involved can connect easily and effectively.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.

Outcomes Based Healthcare supports outcome-based approaches to the healthcare system. With a unique approach to co-creating outcomes with patients, and through academic and technical rigour to the process of measuring and contracting for outcomes. Developing technology products that support commissioners/payors, health providers track and measure outcomes for population segments; linking health and non-health datasets and using big data to predict health outcomes through machine-learning techniques; smartphone app development in predicting Patient Reported Outcomes. Our team has a diverse set of backgrounds in medicine, business, economics, computer science and web technology- directed to do what we love the most: helping design care that fits around people and enabling the health system to do this through technology.